John F. Ginascol - Feb 18, 2022 Form 4 Insider Report for ABBOTT LABORATORIES (ABT)

Role
EXECUTIVE VICE PRESIDENT
Signature
/s/ John F. Ginascol by Jessica H. Paik, Attorney-in-Fact
Stock symbol
ABT
Transactions as of
Feb 18, 2022
Transactions value $
$0
Form type
4
Date filed
2/23/2022, 07:15 PM
Previous filing
Oct 27, 2021
Next filing
Mar 2, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ABT Common shares without par value Award $0 +17.2K +15.17% $0.00 131K Feb 18, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ABT Option (right to buy) Award $0 +80.4K $0.00 80.4K Feb 18, 2022 Common Shares 80.4K $117.58 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes.
F2 Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 26,793 on February 18, 2023, 26,793 on February 18, 2024, and 26,794 on February 18, 2025.